Epidemiology of NHP-drug interactions: Identification and evaluation

Current Drug Metabolism

Volumn 9, Issue 10, 2008, Pages 1049-1054

  Brulotte, J ^a   Vohra, S ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Faculty of Medicine   (Canada)

Author keywords

Active surveillance; Adverse event reporting; Adverse events; Herbal medicine; Natural health product; NHP drug interactions; Safety

Indexed keywords

ASCORBIC ACID; CYCLOSPORIN; DIGOXIN; GINGER EXTRACT; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; INDINAVIR; NATURAL PRODUCT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENPROCOUMON; SEROTONIN UPTAKE INHIBITOR; STEROID; THEOPHYLLINE; VITAMIN; WARFARIN;

ALTERNATIVE MEDICINE; AYURVEDA; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG CONTAMINATION; DRUG EFFICACY; DRUG LABELING; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; EPIDEMIOLOGICAL DATA; GENETIC HETEROGENEITY; HERBAL MEDICINE; HUMAN; PRIMARY HEALTH CARE; REVIEW; UNSPECIFIED SIDE EFFECT; WELLBEING; HERB DRUG INTERACTION; KNOWLEDGE;

COMPLEMENTARY THERAPIES; HERB-DRUG INTERACTIONS; HUMANS; KNOWLEDGE;

EID: 62749195608     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920008786927749     Document Type: Review

References (97)

1. Natural Health Products Directorate- Health Canada. Drugs and health products. http://www.hc-sc.gc.ca/dhp-mps/prodnatur/index_e.html. (accessed May 15, 2007).
2. Newall, C.A.; Anderson, L.A.; Phillipson, J.D. Herbal Medicines: A Guide for Health-care Professionals, 1st ed.; The Pharmaceutical Press: London, 1996.
3. Rieder, M.J. The CAM network - challenges and opportunities. Paediatr. Child Health, 2005, 10(4), 201-202.
4. Vlieger, A.M. Discussing complementary and alternative medicine use for children. Patient Educ. Couns., 2007, 68(1), 1-2.
5. South, M.; Cranswick, N.; Skull, S. Protocol sheet. Adverse events associated with the use of complementary or alternative medicine (CAM), 2007.
6. Health Canada. Adverse reaction information. http://www.hcsc.gc.ca/ dhp-mps/medeff/advers-react-neg/index_e.html#1. (accessed January 22, 2008).
7. World Health Organization. Traditional medicine. http://www.who.int/ mediacentre/factsheets/fs134/en/. (accessed December 5, 2007).
8. World Health Organization. Traditional medicine strategy 2002-2005. http://whqlibdoc.who.int/hq/2002/WHO_EDM_TRM_2002.1.pdf. (accessed August 13, 2007).
9. Kennedy, J. Herb and supplement use in the US adult population. Clin. Ther., 2005, 27(11), 1847-1858.
10. Wheaton, A.G.; Blanck, H.M.; Gizlice, Z.; Reyes, M. Medicinal herb use in a population-based survey of adults: prevalence and frequency of use, reasons for use, and use among their children. Ann. Epidemiol., 2005, 15(9), 678-685.
11. Low, E.; Murray, D.M.; O'Mahony, O.; O'B Hourihane, J. Complementary and alternative medicine use in Irish paediatric patients. Ir. J. Med. Sci., 2008, 177(2), 147-150.
12. Yeh, C.; Tsai, J.; Hui-Me, W.; Lee, S.; Lin, C.; Yang, C. Use of alternative therapy among pediatric oncology patients in Taiwan. Pediatr. Hematol. Oncol., 2000, 17(1), 55-65.
13. Hufford, D.J. Evaluating complementary and alternative medicine: the limits of science and of scientists. JLME, 2003, 31(2), 198-212.
14. Morreim, E.H. A dose of our own medicine: alternative medicine, conventional medicine, and the standards of science. J. Law Med. Ethics, 2003, 31(2), 222-235.
15. Sobel, R. Science and nescience: the issue of alternative medicine. Public Health Rev., 1999, 27(4), 247-260.
16. Pagan, J.A.; Pauly, M.V. Access to conventional medical care and the use of complementary and alternative medicine. Health Aff., 2005, 24(1), 255-262.
17. Natural Health Products Directorate- Health Canada. Baseline natural health products survey among consumers. http://www.hcsc. gc.ca/dhp-mps/ alt_formats/hpfbdgpsa/pdf/pubs/eng_cons_survey_e.pdf. (accessed July 1, 2007).
18. Ernst, E. Prevalence of complementary/alternative medicine for children: a systematic review. Eur. J. Pediatr., 1999, 158(1), 7-11.
19. Fong, D.P.; Fong, L.K. Usage of complementary medicine among children. Aust. Fam. Physician, 2002, 31(4), 388-391.
20. Loman, D.G. The use of complementary and alternative health care practices among children. J. Pediatr. Health Care, 2003, 17(2), 58-63.
21. Ottolini, M.C.; Hamburger, E.K.; Loprieato, J.O.; Coleman, R.H.; Sachs, H.C.; Madden, R.; Brasseux, C. Complementary and alternative medicine use among children in the Washington, DC area. Ambul. Pediatr., 2001, 1(2), 122-125.
22. Simpson, N.; Roman, K. Complementary medicine use in children: extent and reasons. A population-based study. Br. J. Gen. Pract., 2001, 51(472), 914-916.
23. Kelly, J.P.; Kaufman, D.W.; Kelley, K.; Rosenberg, L.; Anderson, T.E.; Mitchell, A.A. Recent trends in use of herbal and other natural products. Arch. Intern. Med., 2005, 165(3), 281-286.
24. Adler, S.R.; Fosket, J.R. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J. Fam. Pract., 1999, 48, 453-458.
25. Quandt, S.A.; Chen, H.; Grzywacz, J.G.; Bell, R.A.; Lang, W.; Arcury, T.A. Use of complementary and alternative medicine by persons with arthritis: results of the National Health Interview Survey. Arthritis Rheum., 2005, 53(5), 748-755.
26. Wood, M.J.; Stewart, R.L.; Merry, H.; Johnstone, D.E.; Cox, J.L. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am. Heart J., 2003, 145(5), 806-812.
27. Cheung, C.K.; Wyman, J.F.; Halcon, L.L. Use of complementary and alternative therapies in community-dwelling older adults. J. Altern. Complement. Med., 2007, 13(9), 997-1006.
28. Simpson, N.; Pearce, A.; Finlay, F.; Lenton, S. The use of complementary medicine in paediatric outpatient clinics. Ambul. Child Health, 1998, 3, 351-356.
29. Sinha, D.; Efron, D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J. Paediatr. Child Health, 2005, 41(1-2), 23-26.
30. Braganza, S.; Ozuah, P.O.; Sharif, I. The use of complementary therapies in inner-city asthmatic children. J. Asthma, 2003, 40(7), 823-827.
31. Reznik, M.; Ozuah, P.O.; Franco, K.; Cohen, R.; Motlow, F. Use of complementary therapy by adolescents with asthma. Arch. Pediatr. Adolesc. Med., 2002, 156(10), 1042-1044.
32. Roy-Byrne, P.P.; Bystritsky, A.; Russo, J.; Craske, M.G.; Sherbourne, C.D.; Stein, M.B. Use of herbal medicine in primary care patients with mood and anxiety disorders. Psychosomatics, 2005, 46(2), 117-122.
33. Deng, G.; Cassileth, B.R. Integrative oncology: complementary therapies for pain, anxiety, and mood disturbance. CA Cancer J. Clin., 2005, 55, 109-116.
34. Boullata, J. Natural health product interactions with medication. Nutr. Clin. Pract., 2005, 20(1), 33-51.
35. Canter, P.H.; Ernst, E. Herbal supplement use by persons aged over 50 years in Britain: frequently used herbs, concomitant use of herbs, nutritional supplements and prescription drugs, rate of informing doctors and potential for negative interactions. Drugs Aging, 2004, 21(9), 597-605.
36. Goldman, R.D.; Rogovik, A.L.; Lai, D.; Vohra, S. Potential interactions of drug-natural health products and natural health products-natural health products among children. J. Pediatr., 2008, 152(4), 521-526.
37. Edwards, J.E.; McQuay, H.J.; Moore, R.A.; Collins, S.L. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J. Pain Symptom Manage., 1999, 18(6), 427-437.
38. Gotzsche, P.C. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control. Clin. Trials, 1989, 10(1), 31-56.
39. Hayashi, K.; Walker, A.M. Japanese and American reports of randomized trials: differences in the reporting of adverse effects. Control. Clin. Trials, 1996, 17(2), 99-110.
40. Ioannidis, J.P.A.; Evans, S.J.W.; Gotzsche, P.C.; O'Neill, R.T.; Altman, D.G.; Schulz, K.; Moher, D. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann. Intern. Med., 2004, 141, 781-788.
41. Ioannidis, J.P.A.; Chew, P.; Lau, J. Standardized retrieval of side effects data for meta-analysis of safety outcomes: a feasibility study in acute sinusitis. J. Clin. Epidemiol., 2002, 55(6), 619-626.
42. Ioannidis, J.P.A.; Lau, J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA, 2001, 285(4), 437-443.
43. Ioannidis, J.P.A.; Lau, J. Improving safety reporting from randomized trials. Drug Saf., 2002, 25(2), 77-84.
44. Loke, Y.K.; Derry, S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin. Pharmacol. [Online] 2001, 1, 3.
45. Martin, R.C 2nd.; Brennan, M.F.; Jaques, D.P. Quality of complication reporting in the surgical literature. Ann. Surg., 2002, 235(6), 803-813.
46. Papanikolaou, P.N.; Churchill, R.; Wahlbeck, K.; Ioannidis, J.P.A. Safety reporting in randomized trials of mental health interventions. Am. J. Psychiatry, 2004, 161(9), 1692-1697.
47. Ernst, E.; Pittler, M.H. Systematic reviews neglect safety issues. Arch. Intern. Med., 2001, 161, 125-126.
48. Moher, D.; Sampson, M.; Campbell, K.; Beckner, W.; Lepage, L.; Gaboury, I. and Berman, B. Assessing the quality of reports of systematic reviews in pediatric complmentary and alternative medicine. BMC Pediatrics [Online] 2002, 2, 3.
49. Elmer, G.W.; Lafferty, W.E.; Tyree, P.T.; Lind, B.K. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Ann. Pharmacother., 2007, 41(10), 1617-1624.
50. Mills, E.; Wu, P.; Johnston, B.C.; Gallicano, K.; Clarke, M.; Guyatt, G. Natural health product-drug interactions: a systematic review of clinical trials. Ther. Drug Monit., 2005, 27(5), 549-557.
51. Roby, C.A.; Anderson, G.D.; Kantor, E.; Dryer, D.A.; Burstein, A.H. St John's wort: effect on CYP3A4 activity. Clin. Pharmacol. Ther., 2000, 67(5), 451-457.
52. Kerb, R.; Bauer, S.; Brockmöller, J.; Roots, I. Urinary 6-β-hydroxycortisol excretion rate is affected by treatment with hypericum extract. Eur. J. Clin. Pharmacol., 1997, 52(Suppl), A186.
53. Markowitz, J.; DeVane, C.; Boulton, D.; Carson, S.; Nahas, Z.; Risch, S. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci., 2000, 66(9), 133-139.
54. Barnes, J.; Anderson, L.A.; Phillipson, D. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J. Pharm. Pharmacol., 2001, 53, 583-600.
55. Barone, G.W.; Gurley, B.J.; Ketel, B.L.; Lightfoot, M.L.; Abul-Ezz, S.R. Drug interaction between St. John's wort and cyclosporine. Ann. Pharmacother., 2000, 34(9), 1013-1016.
56. Breidenbach, T.; Hoffmann, M.; Becker, T.; Schlitt, H.; Klempnauer, J. Drug interaction of St John's wort with ciclosporin. Lancet, 2000, 355(9218), 1912.
57. Nebel, A. Potential metabolic interaction between St. John's wort and theophylline. Ann. Pharmacother., 1999, 33(4), 502.
58. Piscitelli, S.C.; Burstein, A.H.; Chaitt, D.; Alfaro, R.M.; Falloon, J. Indinavir concentrations and St John's wort. Lancet, 2000, 355(9203), 547-548.
59. Rey, J.; Walter, G. Hypericum perforatum (St John's wort) in depression: pest or blessing? [Review] Med. J. Aust., 1998, 169(11), 583-586.
60. Ruschitzka, F.; Meier, P.J.; Turina, M.; Lüscher, T.F.; Noll, G. Acute heart transplant rejection due to Saint John's wort. Lancet, 2000, 355(9203), 548-549.
61. Yue, Q.Y.; Bergquist, C.; Gerdén, B. Safety of St John's wort (Hypericum perforatum). Lancet, 2000, 355(9203), 576-577.
62. Gordon, J.B. SSRIs and St.John's Wort: possible toxicity? Am. Fam. Physician, 1998, 57(5), 950-953.
63. Lantz, M.S.; Buchalter, E.; Giambanco, V. St. John's Wort and antidepressant drug interactions in the elderly. J. Geriatr. Psychiatry Neurol., 1999, 12(1), 7-10.
64. Fugh-Berman, A.; Ernst, E. Herb-drug interactions: review and assessment of report reliability. Br. J. Clin. Pharmacol., 2001, 52(5), 587-595.
65. South, M.; Lim, A.J. Use of complementary and alternative medicine in children: too important to ignore. Paediatr. Child Health, 2003, 39, 573-574.
66. Eisenberg, D.M.; Kessler, R.C.; Foster, C.; Norlock, F.E.; Calkins, D.R.; Delbanco, T.L. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N. Engl. J. Med., 1993, 328(4), 246-252.
67. Sawni-Sikand, A.; Schubiner, H.; Thomas, R.L. Use of complementary/ alternative therapies among children in primary care pediatrics. Ambul. Pediatr., 2002, 2(2), 99-103.
68. Sibinga, E.M.; Ottolini, M.C.; Duggan, A.K.; Wilson, M.H. Parent-pediatrician communication about complementary and alternative medicine use for children. Clin. Pediatr., 2004, 43(4), 367-373.
69. Kelly, K.M.; Jacobson, J.S.; Kennedy, D.D.; Braudt, S.M.; Mallick, M.; Weiner, M.A. Use of unconventional therapies by children with cancer at an urban medical center.see comment. J. Pediatr. Hematol. Oncol., 2000, 22(5), 412-416.
70. Moenkhoff, M.; Baenziger, O.; Fischer, J.; Fanconi, S. Parental attitude towards alternative medicine in the paediatric intensive care unit. Eur. J. Pediatr., 1999, 158(1), 12-17.
71. Winslow, L.C.; Shapiro, H. Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch. Intern. Med., 2002, 162, 1176-1181.
72. Astin, J.A.; Marie, A.; Pelletier, K.R.; Hansen, E.; Haskell, W.L. A review of the incorporation of complementary and alternative medicine by mainstream physicians. Arch. Intern. Med., 1998, 158(21), 2303-2310.
73. Sencer, S.F.; Kelly, K.M. Complementary and alternative therapies in pediatric oncology. Pediatr. Clin. North Am., 2007, 54, 1043-1060.
74. Goldman, S.A. Limitations and strengths of spontaneous reports data. Clin. Ther., 1998, 20(Suppl c), c40-c44.
75. Hartmann, K.; Doser, A.K.; Kuhn, M. Postmarketing safety information: how useful are spontaneous reports? Pharmacoepidemiol. Drug Saf., 1999, 8(Suppl 1), S65-S71.
76. Moride, Y.; Haramburu, F.; Bégaud, B.; Alvarez-Requejo, A.; Chaslerie, A. Under-reporting of adverse drug reactions in general practice. Br. J. Clin. Pharmacol., 1997, 43, 177-181.
77. Alvarez-Requejo, A.; Carvajal, A.; Begaud, B.; Moride, Y.; Vega, T.; Arias, L.H. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur. J. Clin. Pharmacol., 1998, 54, 483-488.
78. Nissen, S.E. ADHD drugs and cardiovascular risk. N. Engl. J. Med., 2006, 354(14), 1445-1448.
79. Charrois, T.L.; Hill, R.L.; Vu, D.; Foster, B.C.; Boon, H.S.; Cramer, K.; Vohra, S. Community identification of natural health product-drug interactions. Ann. Pharmacother., 2007, 41(7), 1124-1129.
80. Vohra, S. Children and chiropractic: what's the harm? Focus Altern. Complemet. Ther., 2004, 9, 12-14.
81. Marketed Health Products Directorate- Health Canada. Draft consensus guidelines: pharmacovigilance planning. http://www.hcsc.gc.ca/ hpfb-dgpsa/tpd-dpt/e2e§ep2_e.pdf. (accessed January 16, 2008).
82. Al-Tajir, G.K.; Kelly, W.N. Epidemiology, comparative methods of detection, and preventability of adverse drug events. Ann. Pharmacother., 2005, 39(7-8), 1169-1174.
83. Jones, H.A.; Metz, J.M.; Devine, P.; Hahn, S.M.; Whittington, R. Rates of unconventional medical therapy use in patients with prostate cancer: standard history versus directed questions. Urology, 2002, 59(2), 272-276.
84. Koren, G.; Randor, S.; Martin, S.; Danneman, D. Maternal ginseng use associated with neonatal androgenization. JAMA, 1990, 264(22), 2866.
85. Awang, D.V. Maternal use of ginseng and neonatal androgenization. JAMA, 1991, 266(3), 363.
86. Fugh-Berman, A. Herb-drug interactions. Lancet, 2000, 355, 134-138.
87. Huang, W.; Wen, K.; Hsiao, M. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J. Clin. Pharmacol., 1997, 37(4), 344-350.
88. Health Canada. Physio Care Lida Dai Dai Hua Jiao Nang Slimming Capsules. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_fpa-ape_2008/ 2008_13-eng.php. (accessed September 14, 2008).
89. Health Canada. Xian Zhi Wei II. http://www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/_fpa-ape_2008/2008_66-eng.php. (accessed September 14, 2008).
90. Health Canada. Health Canada warns consumers not to use vigoureux or any unauthorized products promoted for erectile dysfunction. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2008/ 2008_63-eng.php. (accessed September 14, 2008).
91. Health Canada. Nangen Zengzhangsu (may also be known as Nangen or Nangeng), Sanbianwan, Jiu Bian Wang, Tian Huang Gu Shen Dan, Zui Xian Dan Gong Shi Zi, and Power Up). http://www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/_fpa-ape_2008/2008_96-eng.php. (accessed September 14, 2008).
92. Health Canada. Zhong Hua Niu Bian. http://www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/_fpa-ape_2008/2008_97-eng.php. (accessed September 14, 2008).
93. Health Canada. Health Canada warns consumers not to use Desire or any unauthorized products promoted to enhance sexual performance. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2008/ 2008_80-eng.php. (accessed September 14, 2008).
94. Health Canada. Yogaraja Gulgulu Pills (batch number GK039) and Pilsol Capsule. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_fpa-ape_2008/2008_25-eng.php. (accessed September 14, 2008).
95. Health Canada. Health Canada reminds consumers that some ayurvedic medicinal products contain high levels of heavy metals. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2008/ 2008_73-eng.php. (accessed September 14, 2008).
96. Health Canada. Qili Brand Tongbianling Jiaonang Sincere Brand ChuanXinLian Jiaonang Xiangyao Brand Xiangyao Weian Jiaonang Biflora Brand Fufang Danshen Pian (film-coated) Biflora Brand 306 Xiaoyan Jiedu capsules Xiang Sha Liu Jun Wan. http://www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/_fpa-ape_2008/2008_67-eng.php. (accessed September 14, 2008).
97. Health Canada. Unauthorized health product contains heavy metals. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2008/ 2008_10-eng.php. (accessed September 14, 2008).